We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+21%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
+$311M
Cap. Flow
-$51.2M
Cap. Flow %
-1.8%
Top 10 Hldgs %
74.16%
Holding
31
New
1
Increased
10
Reduced
3
Closed
2
Avg Time Held
8.3 quarters
Top 10 Avg Time Held
9.1 quarters
Top 20 Avg Time Held
8.5 quarters

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$27.8M
2
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$26.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.5M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$120M
2
TSRO
TESARO, Inc.
TSRO
+$16.8M
3
CELG
Celgene Corp
CELG
+$16.2M
4
PBYI icon
Puma Biotechnology
PBYI
+$9.61M
5
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PBYI icon
26
Puma Biotechnology
PBYI
$539M
$16.2M 0.57%
241,991
-190,000
-44% -$9.61M
2014 Q1
10 quarters
AVXS
27
DELISTED
AveXis, Inc. Common Stock
AVXS
$14.5M 0.51%
+352,800
New +$13.4M
2016 Q3
0 quarters
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$10.4M 0.36%
1,279,340
– –
2013 Q2
13 quarters
CDTX icon
29
DELISTED
Cidara Therapeutics
CDTX
$8.55M 0.3%
37,341
– –
2015 Q4
3 quarters
TBRA
30
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-468,000
Closed -$5.88M –
MDVN
31
DELISTED
MEDIVATION, INC.
MDVN
– –
-1,991,112
Closed -$120M –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2016 Portfolio in Review

As of Q3 2016, BB Biotech held 31 positions worth $2.84B, up 12% from $2.53B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

BB Biotech's Q3 2016 filing shows 1 new, 10 increased, 3 reduced and 2 closed positions. Its largest new stake was AveXis, Inc. Common Stock: 352,800 shares worth $14.5M. The largest sale was MEDIVATION, INC., an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • BB Biotech's largest Q3 2016 buy was AveXis, Inc. Common Stock: 352,800 shares worth $14.5M.
  • BB Biotech added most to MacroGenics in Q3 2016, an estimated $27.8M increase.
  • BB Biotech's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $16.8M.
  • BB Biotech fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $120M.
  • BB Biotech's ten largest holdings make up 74% of its $2.84B portfolio in Q3 2016.
  • BB Biotech opened 1 new position and closed 2 in Q3 2016.
  • BB Biotech's portfolio value rose 12% quarter-over-quarter to $2.84B.

Based on BB Biotech's 13F filing for Q3 2016, filed 10 Nov 2016.